Dr. Russell Surasky, a neurologist with dual certification, discusses an experimental drug for Alzheimer’s.

Promising New Drug Slows Alzheimer’s Progression by 35%

There is hope for those suffering from Alzheimer’s disease, as Eli Lilly has developed a new experimental drug that has shown promising results. In a late-stage trial, the drug was found to slow the progression of the disease by 35%. This is great news, as the Alzheimer’s Association predicts that the number of Americans living with Alzheimer’s will almost double by 2050, reaching almost 13 million.

Expert Insights from Double Board Certified Neurologist

To learn more about this exciting development, OAN’s Alicia Summers speaks with Double Board Certified Neurologist, Dr. Russell Surasky. Dr. Surasky provides further insights into the new drug and what it means for those living with Alzheimer’s.

Other Headlines:

• The Arizona Supreme Court orders a trial court hearing Kari Lake’s signature verification challenge to move forward while denying attorney fees.
• A for-profit organization is working to drive advertising dollars away from conservative news outlets.
• Thousands of Oakland school district faculty go on strike over wages and resources.
• Arizona Congressman Andy Biggs tells One America News that if the whistleblower report on Joe Biden receiving money in exchange for policy decisions on behalf of a foreign national is true, it would be the most significant domestic scandal in last 75-years.

Stay up-to-date with the latest news:

• Shares in Telecom Italia (TIM) rose as much as 4% on Friday as the board of the…
• Tesla Inc delivered 75,842 China-made electric vehicles (EVs) in April, down 14.7% from March, data from the China Passenger Car…
• Israel has seized around 190 crypto accounts at crypto exchange Binance since 2021, according to reports.
• U.S. chipmaker Broadcom’s Chief Executive Hock Tan on Friday will try to convince EU antitrust…